Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Horizon Discovery, Sophia Genetics collaborate on NGS reference standards for oncology applications

Published 21 November 2016

Horizon Discovery Group has collaborated with Sophia Genetics on next generation sequencing (NGS) reference standards for oncology applications.

The partnership will work to enhance the quality of NGS-based genetic testing in oncology patient samples.

As per terms of the deal, Horizon’s HDx Reference Standards will be aggregated with Sophia Genetics’ artificial intelligence to provide hospitals and laboratories with precise and quality NGS testing services, assays and genomic data analysis.

Specifically, the current and future users of the Sophia DDM analytical platform can evaluate the quality of their NGS assays.

According to Horizon, the use of HDx Reference Standards will help performance monitoring, as well as reproducibility and repeatability of NGS tests.

Sophia Genetics CEO and co-founder Jurgi Camblong said: “The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data.”

Horizon Discovery Group CEO Dr Darrin Disley said: “Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted.”

Horizon has also partnered with three Chinese diagnostic kit developers to offer HDx reference standards for novel NGS assay development and clinical trials.

The standards will also be used for inclusion as in-kit controls under original equipment manufacturer (OEM) agreements.